Edition:
United States

Boston Scientific Corp (BSX)

BSX on New York Consolidated

27.58USD
25 Jul 2017
Change (% chg)

$-0.04 (-0.14%)
Prev Close
$27.62
Open
$27.72
Day's High
$27.81
Day's Low
$27.51
Volume
4,478,813
Avg. Vol
6,533,120
52-wk High
$28.51
52-wk Low
$19.67

BSX

Chart for BSX

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health,... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $37,822.88
Shares Outstanding(Mil.): 1,369.40
Dividend: --
Yield (%): --

Financials

  BSX Industry Sector
P/E (TTM): 88.17 37.81 15.73
EPS (TTM): 0.31 -- --
ROI: 2.94 8.55 -8.37
ROE: 6.44 13.28 -7.93

BRIEF-Boston Scientific outlines strategy for sustained growth at 2017 investor day

* Boston Scientific outlines strategy for sustained growth at 2017 investor day

Jun 27 2017

BRIEF-Boston Scientific receives CE mark for Vercise Gevia deep brain stimulation system

* Boston Scientific receives CE mark for Vercise™ Gevia™ deep brain stimulation system

Jun 06 2017

BRIEF-Boston Scientific announces positive outcomes from prospective study of bronchial thermoplasty

* Boston Scientific announces positive outcomes from prospective study of bronchial thermoplasty

May 24 2017

BRIEF-Boston Scientific announces positive results from the Reprise III clinical trial

* The Boston Scientific LOTUS™ valve system demonstrated superior efficacy to Corevalve® in global reprise III trial at one year

May 16 2017

BRIEF-Boston Scientific closes Symetis acquisition

* To immediately begin selling Acurate TA and Acurate Neo/TF valve systems in Europe and other geographies outside of U.S. Source text for Eikon: Further company coverage:

May 16 2017

BRIEF-Boston Scientific says positive European registry results for WATCHMAN left atrial appendage closure device

* Boston scientific announces positive european registry results for watchman™ left atrial appendage closure device

May 12 2017

BRIEF-Boston Scientific announces results of study evaluating patients implanted with S-ICD System

* Announced results from U.S. post-market approval study evaluating 'real-world' patients implanted with S-ICD System

May 11 2017

India government panel rejects Boston Scientific plea on stent price caps

NEW DELHI Boston Scientific Corp stands to lose millions of dollars on its high-end heart stent in India after a government panel rejected its request to increase a cap on the price that it can charge for the device.

May 09 2017

BRIEF-Boston Scientific receives FDA approval for resonate family of high-voltage devices

* Boston Scientific receives U.S. FDA approval for resonate™ family of high-voltage devices

May 09 2017

BRIEF-Boston Scientific reports Q1 GAAP EPS $0.21

* Q1 interventional cardiology worldwide sales $605 million versus $560 million

Apr 27 2017

Competitors

Earnings vs. Estimates